Buying guide
Versius vs Maestro in 2026
Comparing 2 humanoid robots across availability, pricing, capabilities, and verified deployments. Current as of 2026.
| Attribute | No image on file | No image on file |
|---|---|---|
| Manufacturer | CMR Surgical | Moon Surgical |
| Form factor | surgical | surgical |
| Maturity | commercial | pilot |
| Availability | internal-onlyenterprise | internal-onlyenterprise |
| Price | Not announced | Not announced |
| Capability claims | — | — |
| Brain | — | — |
| Verified deployments | 2CMR Surgical, CMR Surgical | 1Jacksonville |
| Privacy practices | — | — |
| Sources on file | 18 | 7 |
Editorial summaries
Versius
CMR Surgical's Versius (and Versius Plus) is a modular, multi-arm, soft-tissue minimal-access surgical robot from UK-based CMR Surgical, and the international-soft-tissue archetype of DEPLOY's surgical cluster. Its modular multi-arm architecture is a deliberate contrast to the monolithic design of Intuitive's da Vinci: it is teleoperated and software-driven, capturing telematic, video, and outcome data. On regulatory status (a correction worth recording): Versius is US-FDA-cleared for cholecystectomy via a De Novo authorization in October 2024, with Versius Plus cleared via 510(k) on December 18, 2025 (also cholecystectomy) and a gynecology 510(k) submitted April 29, 2026 (pending); it is not broadly 'US-pending', only the gynecology indication is. It is CE-marked and commercial across Europe, Latin America, AMEA, and Australia. As enterprise B2B surgical equipment sold to hospitals, there is no consumer price.
Maestro
Moon Surgical's Maestro is a laparoscopic surgical-assistant platform (it holds and positions instruments and the endoscope alongside the surgeon, not a full master-slave teleoperated replacement system) and the assistive-laparoscopy archetype of DEPLOY's surgical cluster, editorially distinct from the replacement-robotics of Intuitive, Medtronic, and CMR. Its ScoPilot software is shipped AI (NVIDIA Holoscan-powered) for intraoperative scope control. On regulatory status (a correction worth recording): the Maestro received FDA 510(k) clearance K240598 on June 5, 2024 (not December 2023), and ScoPilot was FDA-cleared in 2025 with a Predetermined Change Control Plan. As enterprise B2B surgical equipment, there is no consumer price.
Machine-readable: this page as markdown.